Hinova Pharmaceuticals (SHSE:688302) Research & Development: ¥117.32 Mil (TTM As of Mar. 2026)


SHSE:688302 Hinova Pharmaceuticals Inc SHSE:688302
26 GF Score
Price ¥35.05
! 2 Warning Signs
View Full Analysis

What is Hinova Pharmaceuticals Research & Development?

Hinova Pharmaceuticals SHSE:688302 +6.02% 26 Research & Development is ¥117.32 Mil as of Mar. 2026. GuruFocus rates SHSE:688302 with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hinova Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was ¥29.38 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥117.32 Mil.

Hinova Pharmaceuticals  (SHSE:688302) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hinova Pharmaceuticals Research & Development Related Terms

Hinova Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Hinova Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hinova Pharmaceuticals Research & Development Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 264.93 251.37 248.27 174.03 112.71

Hinova Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.77 32.20 31.80 23.94 29.38
SHSE:688302
26GF Score
Hinova Pharmaceuticals Inc SHSE:688302
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hinova Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥117.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥117.32 Mil mean?
Hinova Pharmaceuticals (SHSE:688302) has a Research & Development of ¥117.32 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Hinova Pharmaceuticals and its competitors.
Is Hinova Pharmaceuticals' Research & Development too high?
Hinova Pharmaceuticals' current Research & Development is ¥117.32 Mil. Overall, Hinova Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Research & Development compare to VRTX and REGN?
Hinova Pharmaceuticals' Research & Development of ¥117.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hinova Pharmaceuticals and its competitors. Hinova Pharmaceuticals's current Research & Development is ¥117.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Research & Development of ¥117.32 Mil. The current Research & Development is ¥117.32 Mil. Hinova Pharmaceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Research & Development is ¥117.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hinova Pharmaceuticals Business Description

Address No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
26GF Score

Get the complete analysis for SHSE:688302

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥35.05
Price